| Title: |
Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study. |
| Authors: |
Ruscica, Massimiliano1,2 (AUTHOR) massimiliano.ruscica@unimi.it, Macchi, Chiara1 (AUTHOR), Giuliani, Angelica3 (AUTHOR), Rizzuto, Alessandra Stefania4 (AUTHOR), Ramini, Deborah5 (AUTHOR), Sbriscia, Matilde3 (AUTHOR), Carugo, Stefano2,4 (AUTHOR), Bonfigli, Anna Rita6 (AUTHOR), Corsini, Alberto1 (AUTHOR), Olivieri, Fabiola3,5 (AUTHOR), Sabbatinelli, Jacopo3,7 (AUTHOR) j.sabbatinelli@univpm.it |
| Source: |
Cardiovascular Diabetology. 8/24/2023, Vol. 22 Issue 1, p1-12. 12p. |
| Subject Terms: |
*TYPE 2 diabetes, *MAJOR adverse cardiovascular events, *DIABETIC nephropathies, *CARDIOVASCULAR diseases, *BIOMARKERS, *DYSLIPIDEMIA |
| Abstract: |
Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality, being twofold to fourfold more common in patients with type 2 diabetes mellitus (T2DM) than in individuals without diabetes. However, despite this decade-old knowledge, the identification of a specific prognostic risk biomarker remains particularly challenging. Methods: Taking advantage of a large sample of Caucasian patients (n = 529) with a diagnosis of T2DM followed for a median of 16.8 years, the present study was aimed at testing the hypothesis that fasting serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels could be prognostic for major adverse cardiovascular events (MACE) and all-cause mortality. Results: Median levels of PCSK9 were 259.8 ng/mL, being higher in women compared to men and increasing even more in the presence of a complication (e.g., diabetic kidney disease). PCSK9 positively correlated with markers of blood glucose homeostasis (e.g., HbA1c, fasting insulin and HOMA-IR) and the atherogenic lipid profile (e.g., non-HDL-C, apoB and remnant cholesterol). Serum PCSK9 predicted new-onset of MACE, either fatal or non-fatal, only in women (Odds Ratio: 2.26, 95% CI 1.12–4.58) and all-cause mortality only in men (Hazard Ratio: 1.79, 95% CI 1.13–2.82). Conclusions: Considering that up to two-thirds of individuals with T2DM develop ASCVD in their lifetime, the assessment of circulating PCSK9 levels can be envisioned within the context of a biomarker-based strategy of risk stratification. However, the sex difference found highlights an urgent need to develop sex-specific risk assessment strategies. Trial registration: It is a retrospective study. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cardiovascular Diabetology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
